Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study

Autor: Itamar Raz, Gil Leibowitz, Benjamin M. Scirica, Cheryl Wei, W. H.-H. Sheu, Eugene Braunwald, J. L. Sendon, Avivit Cahn, Deepak L. Bhatt, Ofri Mosenzon, Boaz Hirshberg, György Jermendy, KyungAh Im
Rok vydání: 2015
Předmět:
Zdroj: Diabetes, Obesity and Metabolism. 17:487-494
ISSN: 1462-8902
Popis: Aims To study the effects of saxagliptin, a dipeptidyl peptidase-4 inhibitor, on glycaemic stability and β-cell function in the SAVOR-TIMI 53 trial. Methods We randomized 16 492 patients with type 2 diabetes (T2D) to saxagliptin or placebo, added to current antidiabetic medications, and followed them for a median of 2.1 years. Glycaemic instability was defined by: (i) a glycated haemoglobin (HbA1c) increase of ≥0.5% post-randomization; (ii) the initiation of new antidiabetic medications for ≥3 months; or (iii) an increase in dose of oral antidiabetic medication or ≥25% increase in insulin dose for ≥3 months. β-cell function was assessed according to fasting homeostatic model 2 assessment of β-cell function (HOMA-2β) values at baseline and at year 2 in patients not treated with insulin. Results Compared with placebo, participants treated with saxagliptin had a reduction in the development of glycaemic instability (hazard ratio 0.71; 95% confidence interval 0.68–0.74; p
Databáze: OpenAIRE